Baird Analyst Michael Ha on UnitedHealth (UNH) Stock: Cautious Outperform Rating Amidst DOJ Probe

Near-Term Caution on UnitedHealth Group (UNH)

• ⚠️ Michael Ha maintains an outperform rating on UNH but expresses significant near-term caution due to ongoing uncertainties.
• 📉 The stock is described as a "falling knife," with investors awaiting 2025 guidance to stabilize sentiment and stop the immediate sell-off.
• 📌 Without clear guidance, investors are hesitant to "buy the dip," anticipating potential further downside.

Potential Stock Bottom and Valuation

• 🎯 Investors are looking at pre-Affordable Care Act (ACA) valuations, suggesting a potential PE multiple of 9x on 2026 earnings.
• 💰 This valuation could place the stock price around $228, representing a further 15% downside from current levels.
• ⏳ The market is in a "vacuum" regarding guidance, with the next earnings report in the summer, leading to a prolonged period of uncertainty.

Impact of New CEO and Business Risks

• 🍳 A new CEO might "kitchen sink" the earnings, potentially leading to a rough second half of the year for the stock.
• ⚠️ The company's decision not to commit to 2025 guidance on their second-quarter earnings call exacerbates the prolonged uncertainty.
• 🔗 This uncertainty, coupled with business risks, creates a tough near-term setup for UnitedHealth Group.

Shift in Analyst Perspective and Optimum Health Concerns

• 💡 The situation is fundamentally different from the February drop; previously, investors were willing to buy the dip, but now the issues are more deeply rooted.
• 💔 The primary concern is with Optimum Health, UnitedHealth's value-based care segment, which was expected to drive future growth and expansion.
• 📉 Any "cracks" in Optimum Health are viewed more seriously than other business issues, making analysts very cautious.
• 🎯 While the stock is down significantly, further diligence is needed on Optimum Health, leading to a reduced price target from over $600 to around $350.